Cargando…

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. We recruited 64 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Zhichao, Li, Feng, Zhang, Chao, Zhu, Lei, Shi, Yehui, Zhao, Gang, Bai, Xu, Hassan, Shafat, Liu, Xinyue, Li, Ting, Xing, Peipei, Zhao, Jun, Zhang, Jin, Xing, Ruwei, Teng, Sheng, Yang, Yun, Chen, Kexin, Yang, Jilong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395676/ https://www.ncbi.nlm.nih.gov/pubmed/30816108 http://dx.doi.org/10.1038/s12276-019-0221-7

Ejemplares similares

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
por: Liao, Zhichao, et al.
Publicado: (2020)

Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China
por: Li, Feng, et al.
Publicado: (2017)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
por: Lu, Jia, et al.
Publicado: (2022)

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas
por: Liao, Zhichao, et al.
Publicado: (2022)

Clinicopathologic features, prognostic factors, and outcomes of visceral sarcomas: A retrospective 12-year single-center study
por: Yang, Songwei, et al.
Publicado: (2022)

The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids
por: Wei, Junqiang, et al.
Publicado: (2020)

BRAF mutation and its inhibitors in sarcoma treatment
por: Liu, Haotian, et al.
Publicado: (2020)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China
por: Liao, Zhichao, et al.
Publicado: (2019)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting
por: Yang, Jilong, et al.
Publicado: (2022)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Roles of low-density lipoprotein receptor-related protein 1 in tumors
por: Xing, Peipei, et al.
Publicado: (2016)

Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
por: Liu, Kuisheng, et al.
Publicado: (2017)

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
por: Peng, Qiu-Xia, et al.
Publicado: (2017)

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma
por: Zhang, Chao, et al.
Publicado: (2022)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway
por: Xia, Liang, et al.
Publicado: (2022)

Pan-Soft Tissue Sarcoma Analysis of the Incidence, Survival, and Metastasis: A Population-Based Study Focusing on Distant Metastasis and Lymph Node Metastasis
por: Liu, Haotian, et al.
Publicado: (2022)

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
por: Yu, Wenxi, et al.
Publicado: (2022)

Advanced alveolar soft part sarcoma responds to apatinib
por: Zhou, Yong, et al.
Publicado: (2017)

VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes
por: Li, Guangxin, et al.
Publicado: (2018)

Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report
por: Hou, Zhenyu, et al.
Publicado: (2020)

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling
por: Cai, Xiaomin, et al.
Publicado: (2020)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution
por: Wang, Yitian, et al.
Publicado: (2019)

Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review
por: Lin, Yan, et al.
Publicado: (2022)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Treatment of uterine high-grade endometrial stromal sarcoma with apatinib combined with chemotherapy: A case report
por: Zhang, Ying, et al.
Publicado: (2019)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang, Jiaqiang, et al.
Publicado: (2021)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
por: Yu, Jiangtao, et al.
Publicado: (2019)

Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)
por: Shi, Liang, et al.
Publicado: (2022)

The use of apatinib in treating primary pleural synovial sarcoma: A case report
por: Chen, Sumei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3luho3rkbv69hqn1cksr7ltf71